3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Uveal Melanoma
1
Substance Withdrawal Syndrome
1
Retinal Diseases
1
Opioid-Related Disorders
1
Myocardial Reperfusion Injury
1
Melanoma
1
Macular Degeneration
1
Lymphoma, Follicular
1
Choroid Diseases
1
Cardiotoxicity
1
Interventions
Ipilimumab
3
Triamcinolone Acetonide
2
Ranibizumab
2
Nivolumab
2
Amplified Fragment Length Polymorphism Analysis
2
treosulfan
1
salicylhydroxamic acid
1
aldesleukin
1
Ultrasonography
1
Tramadol
1
Temozolomide
1
Tamoxifen
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Sunitinib
1
Sorafenib
1
Rose Bengal
1
Radiosurgery
1
Physical Examination
1
Pharmacogenomic Testing
1
Interviews as Topic
1
Immunotherapy
1
Ibuprofen
1
Gemcitabine
1
Eye Enucleation
1
Cyclophosphamide
1
Cisplatin
1
Chemotherapy, Adjuvant
1
CTLA-4 Antigen
1
Brachytherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Uveal Melanoma
×
salicylhydroxamic acid
×
Clear all
NCT00811200
2009-07-02
TORR
Leiden University Medical Center
Phase 2/3
Unknown
220 enrolled